Novo Nordisk Facing Class Action Lawsuit for Alleged Anticompetitive Practices in GLP-1 Drug Market
Novo Nordisk, a leading pharmaceutical company, is facing a proposed class action lawsuit filed by a South Carolina-based drug company. The suit alleges that Novo Nordisk engaged in anticompetitive practices to extend its monopoly over the GLP-1 drug Victoza, thereby delaying the entry of generic competitors into the market. GLP-1 receptor agonists, such as Victoza,…